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ABSTRACT
Acute kidney injury (AKI) represents a worldwide public
health issue of increasing incidence, with a signiﬁcant morbi-
mortality. AKI treatment mostly relies on supportive
manoeuvres in the absence of speciﬁc target-oriented therapy.
The pathophysiology of AKI commonly involves ischaemia/re-
perfusion (I/R) events, which cause both immune and meta-
bolic consequences in renal tissue. Similarly, at the time of
kidney transplantation (KT), I/R is an unavoidable event
which contributes to early graft dysfunction and enhanced
graft immunogenicity. Mesenchymal stromal cells (MSCs)
represent a heterogeneous population of adult, ﬁbroblast-like
multi-potent cells characterized by their ability to differentiate
into tissues of mesodermal lineages. Because MSC have de-
monstrated immunomodulatory, anti-inﬂammatory and tissue
repair properties, MSC administration at the time of I/R and/
or at later times has been hypothesized to attenuate AKI sever-
ity and to accelerate the regeneration process. Furthermore,
MSC in KT could help prevent both I/R injury and acute rejec-
tion, thereby increasing graft function and survival. In this
review, summarizing the encouraging observations in animal
models and in pilot clinical trials, we outline the beneﬁt of
MSC therapy in AKI and KT, and envisage their putative role
in renal ischaemic conditioning.
Keywords: acute kidney injury, ischaemia/reperfusion, ischaemic
conditioning, kidney transplantation, mesenchymal stromal cells
INTRODUCTION
Acute kidney injury (AKI) is a broad clinical syndrome, cur-
rently deﬁned as a rapid fall of glomerular ﬁltration rate as re-
ﬂected by an acute rise of serum creatinine and/or a decline in
urine output [1]. The incidence of AKI is generally 5–7.5% in
all acute care hospitalizations, but it accounts for up to 20% of
admissions to intensive care units. Furthermore, ∼30–40% of
all cases of AKI during hospitalization are observed in operat-
ive settings, and particularly after cardiovascular surgery. AKI
commonly involves tissue damage caused by transient ischae-
mia and reperfusion (I/R) [2]. The reduction or interruption
of renal perfusion with a subsequent reﬂow induces signiﬁcant
cell metabolism perturbations and tissue inﬂammation. One
of the paradigms of renal I/R is kidney transplantation (KT).
Indeed, graft procurement, storage and transplantation re-
quires the necessary temporary, and often predictable, inter-
ruption of renal blood ﬂow. Still, such unavoidable I/R events
contribute to early graft dysfunction and enhanced graft im-
munogenicity [3].
Treatment of AKI remains largely supportive, including
ﬂuid maintenance, vasoactive drugs, cytoprotective therapy
and extra-renal epuration [4]. Recent advances in deciphering
the pathophysiology of renal ischaemia/reperfusion injury
(IRI) led to novel therapies, including non-invasive ap-
proaches of renal conditioning. Here, we discuss the putative
role of mesenchymal stromal cell (MSC) therapy in AKI, as
well as in KT.
© The Author 2014. Published by Oxford University Press
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FEATURES AND PROPERTIES OF MSC
MSC represent a heterogeneous population of adult, ﬁbro-
blast-like multi-potent cells characterized by their ability to
differentiate into tissues of mesodermal lineages, including
adipocytes, chondrocytes and osteocytes [5]. MSC can be iso-
lated from various sources, including bone marrow, umbilical
cord, adipose tissue or muscle [6]. According to the 2006 con-
sensus of the International Society of Cellular Therapy, the
distinctiveness of MSC relies on the following standard cri-
teria: adherence to plastic surfaces; potential to differentiate
into osteocytes, adipocytes and chondrocytes under standard
in vitro differentiating conditions; surface expression of
CD105, CD73 and CD90 and lack of the haematopoietic
markers, CD45, CD34, CD14, CD11b, CD79a and HLA-DR.
A large number of in vitro and in vivo studies have docu-
mented the anti-inﬂammatory and immunoregulatory proper-
ties of MSC in both the innate and the adaptive immune
systems. Indeed, MSC have been reported to prompt T-cell ex-
pansion towards a regulatory phenotype. These regulatory T
cells (Treg), including the naturally occurring CD25+FoxP3+
Treg in the thymus and the adaptive Treg in periphery, are
responsible for maintaining tolerance to self-antigens and con-
trolling excessive immune response to external antigens [7].
The potential mechanisms of MSC-induced Treg differen-
tiation may involve (i) direct cell–cell contacts, (ii) the pro-
duction of prostaglandin E2 and transforming growth factor
β-1 (TGFβ-1) and (iii) the release of a non-classical HLA class
I molecule, HLA-G5 [8]. In addition, micro-vesicles derived
from MSC may help transfer cellular materials, including
RNA and proteins, and organelles to neighbouring cells
[9–11]. Interestingly, various in vitro observations suggest that
the culture conditions, the types and concentrations of cyto-
kines in the milieu and the activation status of T cells at the
time of exposure to MSCs also inﬂuence their ﬁnal differen-
tiation [12]. In addition to their impact on T-cell fate, MSCs
inﬂuence macrophage outcomes, with a preferential shift
towards an anti-inﬂammatory immunosuppressive M2 pheno-
type [13, 14]. M2 macrophages have been implicated in the
generation and maintenance of Treg. Finally, MSC treatment
in vitro inhibits antigen-presenting cells (APC), which further
favours Treg expansion through the release of TGFβ [15]. In
vivo, the beneﬁcial MSC-induced polarization of T cells
towards a Treg phenotype has been demonstrated in numer-
ous experimental models of autoimmune and inﬂammatory
diseases, such as systemic lupus erythematosus, ﬁbrillin-mutated
systemic sclerosis or colitis.
In addition to these immunoregulatory properties, MSC
exert tissue repair functions in damaged organs [16]. In par-
ticular, experimental observations have demonstrated their
protective effect in AKI, as detailed infra. Following a renal
IRI, MSCs reduce inﬂammation and accelerate vascular supply
[17]. Indeed, single or repeated injections of MSC or MSC-
derived micro-vesicles after injury accelerate functional recov-
ery of the kidneys [16], and improve survival in a lethal model
of AKI [10]. MSC activate endogenous cellular repair pro-
grammes by releasing various growth factors such as ﬁbroblast
growth factor, hepatocyte growth factor, insulin-like growth
factor (IGF), keratinocyte growth factor, monocyte chemoat-
tractant protein-1, stromal cell-derived factor-1 (SDF-1) and
vascular endothelial growth factor. Additional MSC-related
mediators, including IL-10, IL-6, TGF-β or nitric oxide (NO),
may further facilitate a local anti-inﬂammatory state, thereby
allowing the healing of damaged tissues. Moreover, the expan-
sion of surviving renal tubular cells observed with the admin-
istration MSC or MSC derivatives result from the induction of
pro-survival genes and down-regulation of pro-apoptotic
genes. Finally, MSC-derived micro-vesicles help to rapidly
restore adenosine triphosphate (ATP) supply following IRI by
transferring mitochondria into the damaged cells [10, 11].
Such tissue repair effect of MSC therapy in AKI has also been
successfully observed in other organs, like the liver, lungs,
heart and intestines [16].
Altogether, these in vitro and in vivo observations highlight
the signiﬁcant potential of immunomodulation, anti-inﬂam-
mation and tissue repair of MSC via both direct cell–cell inter-
actions and the release of paracrine factors.
PATHOPHYSIOLOGY OF RENAL I /R
A sustained interruption of kidney perfusion is associated with
a rapid drop in oxygen partial pressure and nutrient concen-
tration, which leads to tissular and cellular events eventually
causing ‘ischaemic damage’ [2, 3]. At the cellular level, ischae-
mia causes a rapid depletion of the energy supply, i.e. ATP, of
renal tubular cells since oxidative phosphorylation can no
longer proceed in the mitochondria in the absence of oxygen
(Figure 1). Anaerobic glycolysis transiently allows a residual
production of ATP, but is associated with the intracellular
accumulation of lactate and the acidiﬁcation of cell cytosol,
which further perturbs mitochondrion and cell functions. In
addition, the lack of energy delivery induces the disorganiz-
ation of the cytoskeleton, the disruption of intercellular tight
junctions, the loss of cell polarity and the dysfunction of mem-
brane ion transporters, including the Na+/K+-ATPase [2, 18].
Consequently, epithelial and endothelial cells detach from
their basal membrane and obstruct tubular and vascular
lumens, respectively. The loss of tubular and vascular per-
meability causes a major accumulation of ﬂuids in the intersti-
tium, which further delays kidney reperfusion and prolongs
the ischaemic insult. Moreover, renal cell injury caused by I/R
is associated with a massive and local production of reactive
oxygen species (ROS), which are responsible for the detrimen-
tal oxidation of proteins, lipids, membranes and nucleic acids
of both epithelial and endothelial cells [19].
In addition to all these metabolic consequences, IRI is
associated with a signiﬁcant inﬂammatory reaction character-
ized by the expression and activation of endothelial adhesion
molecules, integrins and selectins. Such ‘sterile inﬂammation’
is characterized by the release of danger-associated molecular
pattern molecules, which, in turn, activate the innate immune
responses via the Toll-like receptors, and recruit inﬂammatory
cells [20]. The deleterious impact of I/R-associated inﬂam-
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receptors, such as chemokine receptor-2, chemokine receptor-
7, CXC chemokine receptor-4 as well as the local production
of ROS, tumour necrosis factor-α and interleukin-1β [21]. In
addition, there is a sustained ampliﬁcation of IgG1 antibodies
directed against an antigen encountered in the days following
renal I/R [22]. Interestingly, the total amount of antigen-un-
speciﬁc IgG1 and the number of B lymphocytes remain un-
changed during this period, but the number of antigen-
speciﬁc lymphocytes increases. This effect is lost in mice
deﬁcient in complement factor B that lacks a functional
alternative pathway of complement, as well as in IL10-deﬁcient
mice. These observations suggest that kidney IRI leads to a rise
in antibody production against heterologous antigens [22].
Still, the role of B lymphocytes at the time of IRI remains
unclear, with conﬂicting observations as to whether these cells
are protective or harmful to the ischaemic kidney [23, 24].
Furthermore, the activation of naïve T cells through antigen
presentation by dendritic cells may contribute to the enhanced
kidney immunogenicity following IRI [25]. All these inﬂam-
matory and immune consequences may play an even more
important role in renal I/R at the time of KT, as detailed infra.
A better understanding of the tissular and cellular phenomena
associated with renal IRI would thus help exploit them to
prevent or attenuate the ischaemic damage.
MSC THERAPY IN RENAL IRI
MSC are characterized by signiﬁcant properties of immunomo-
dulation, anti-inﬂammation and tissue repair, which could be
advantageous against renal IRI [16]. Indeed, MSC therapy may
act all along the IRI process, from attenuating ischaemia-related
metabolic disturbances to preventing reperfusion-associated
inﬂammation and facilitating tissue regeneration (Figure 1).
As summarized above, both direct cell–cell interactions and
the release of paracrine or endocrine factors have been de-
scribed in MSC therapy. Furthermore, the sole administration
of MSC derivatives, like micro-vesicles and conditioned
media, has also demonstrated beneﬁcial effects in distinct
models of renal IRI.
To the best of our knowledge, the administration of MSC
or MSC derivatives in most, if not all, experimental protocols
of MSC therapy in renal IRI occurs after the injury [16]. The
impact of MSC in renal ischaemic conditioning (IC) remains
thus ill-deﬁned. The principle of IC consists in exposing an
organ to repeated episodes of brief (3–5 min) ischaemia by ar-
terial clamping/unclamping before a prolonged ischaemia.
Numerous experimental models using the heart, intestine,
brain, liver or kidneys have shown that IC leads to a low-
energy tissular and cellular status, which helps preserve cell
metabolism and architecture, reduces inﬂammation at the
time of reperfusion and accelerates functional recovery of the
organ [26, 27]. Interestingly, renal IC can also be achieved by
applying brief and repeated episodes of I/R to a remote organ,
like the limbs or the intestine [28]. The mechanisms of remote
IC remain poorly characterized and may involve the auton-
omous neurogenic cascade, as well as the secretion of diverse
biochemical messengers into the bloodstream [20, 28, 29].
Characterizing the signal transduction pathways involved in
both direct and remote IC is urgently required to develop and
validate non-invasive approaches for IC. Indeed, fractionated
episodes of ischaemia surgically performed on the renal ar-
teries might damage the vascular structures and/or induce
platelet aggregation with micro-embolization into the renal
parenchyma, thereby worsening reperfusion. Various targets
have been pharmacologically tested in rodent models of renal
F IGURE 1 : Schematic view of the putative beneﬁts of mesenchymal stromal cells (MSC) on renal ischaemia/reperfusion injury (IRI). MSC
may modulate the inﬂammatory and immune response and restore cell metabolism, thereby attenuating tissue damage and accelerating the
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IRI, as summarized in Table 1. Whether MSC therapy rep-
resents a safe non-invasive method for renal IC remains to be
determined.
In anaesthetized rats with I/R-induced AKI, the intra-
carotid administration of MSC either immediately or 24 h after
renal IRI resulted in signiﬁcantly improved renal function,
higher proliferative and lower apoptotic indexes, as well as
lower renal injury and unchanged leucocyte inﬁltration scores
[30]. Using in vivo two-photon laser confocal microscopy,
ﬂuorescence-labelled MSC could be detected in glomeruli
within the ﬁrst hour after cell infusion. Cell migration and
recruitment to the injured tissue may follow an SDF-1/
CXCR4 (stromal cell-derived factor 1) and CXCR7 gradient
[31]. However, within 3 days of administration, none of the
administered MSC had differentiated into a tubular or endo-
thelial cell phenotype. Similarly, a C57BL/6 mouse model of
liver IRI infused with C57BL/6 MSC constitutively expressing
DsRed-ﬂuorescent protein and radioactively labelled with Cr-
51 demonstrated that MSC are short-lived and that viable
MSC do not pass the lungs. Thus, long-term beneﬁcial effects
of MSC appear primarily mediated by paracrine actions and
not by their engraftment and trans-differentiation into target
cells [32]. Several experimental models using different animal
species have suggested that the beneﬁcial effect of MSC on
renal tubular cells proliferation following IRI may be linked to
their ability to suppress oxidative stress and attenuate the
inﬂammatory response [33, 34]. At later times after injury
(i.e. 6–10 weeks), MSC therapy also improves functional par-
ameters and reduces progression of renal ﬁbrosis, with reduced
mRNA expression of type I collagen and vimentin [35].
Such a global protective effect appears to be mostly
mediated by modulation of the inﬂammatory response and/or
hypoxia, which blocks the epithelial–mesenchymal transition.
Various experimental manipulations have successfully been
conducted to further enhance the protective ability of MSC in
renal IRI, including genetic overexpression of BMP-7 or HGF
and co-administration with pharmacological agents. Hence,
the concomitant application of MSC and darbepoetin-α after
IRI in rats leads to reduced tissue injury and better renal recov-
ery in comparison with MSC or darbepoetin-α alone [36]. In
addition, in vitro hypoxic conditioning of MSC before their in-
fusion ameliorates their recruitment and viability into the
injured tissue, as well as their tissue repair capabilities via an
increased secretion of pro-angiogenic, anti-apoptotic and mi-
togenic factors. Neutralization of either CXCR4 or CXCR7 im-
paired the improved therapeutic potential of MSC cultured in
hypoxic conditions [31]. Similarly, MSC preconditioning with
type 1 IGF (IGF-1) before administration improves cell
migration capacity and restores normal renal function after
AKI [37].
Besides direct cell–cell interactions, the renal protective efﬁ-
cacy of MSC may involve paracrine factors inducing resistance
to apoptosis and favouring proliferation of surviving tubular
cells [38]. A single administration of MSC-derived micro-
vesicles immediately after IRI protects rats from AKI by inhibiting
apoptosis and stimulating tubular epithelial cell proliferation,
thereby signiﬁcantly reducing the impairment of renal func-
tion and preventing chronic renal damage. In an alternative
model of glycerol-induced AKI in SCID mice, the sole infu-
sion of micro-vesicles derived from human bone marrow
MSC accelerated morphologic and functional kidney recovery
to a similar extent as classical MSC therapy. MSC-derived exo-
somes are thought to vehicle a speciﬁc subset of cellular mRNA
implicated in the mesenchymal phenotype and in the control of
transcription, proliferation and immunoregulation [39].
On the basis of these promising observations in animal
models of renal IRI, clinical studies using allogenic or autolo-
gous MSC in the settings of ischaemic AKI at the time of
cardiac surgery have been initiated (www.clinicaltrials.gov).
According to preliminary results of phase I and II trials invol-
ving MSC therapy (#NCT00733876; #NCT01602328), no
major adverse events have been reported. Still, essential ques-
tions remain to be addressed, including the route of delivery,
the adequate number/volume of MSC infusion, the timing and
frequency of MSC administration before and/or after renal IRI
and the clinical and immunological tolerance to these cells
[16]. No data regarding the impact of MSC therapy on kidney
protection and the eventual regeneration following AKI are
currently available in man.
MSC THERAPY IN THE SPECIF IC SETTING
OF KT
KT represents the best treatment for patients with end-stage
renal disease. According to the latest reports from EuroTrans-
plant (www.eurotransplant.org), graft survival rates at 1, 3 and
5 years following KT from a deceased donor are 84, 78 and
68%, respectively. When living donors are considered, graft
survival reaches 93, 89 and 82% at 1, 3 and 5 years following
KT. The main causes of graft loss are acute rejection (AR) and
chronic allograft nephropathy (CAN). Although encouraging,
these numbers about graft survival reﬂect the possibility to
further improve KT efﬁciency, and emphasize the interplay
between immune and non-immune factors. Indeed, KT
necessarily delivers a major histocompatibility complex-
Table 1. Drug-mediated renal ischaemic conditioning in rodent models
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incompatible graft from a donor to a recipient. This simul-
taneously triggers the activation of both graft-destructive effec-
tor T cells and protective Treg. The outcome of the renal graft
mostly depends on the balance between such opposing cell
populations. Consequently, current research programmes
further investigate the immune cascades at the time of KT,
with particular focus on the role of complement factors, IL-10
and B and Treg cells. In addition, the optimal timing for inter-
ventions modulating the humoral response still needs to be ad-
dressed. The unfortunate consequences of renal I/R are cell
death and tubular atrophy as well as irreversible deposits of
collagen in the interstitium. This condition, formerly described
as CAN, is associated with a sustained status of hypoxia and a
shortened duration of graft survival [40]. There is evidence
that CAN is also related to low-grade antibody-mediated rejec-
tion as well as to antibody-independent functions of B cells
(i.e. antigen presentation, lymphoid neogenesis). In addition
to these acute and chronic immune events, long-term graft
survival is also inﬂuenced by the quality of the graft at the time
of its transplantation, and particularly by the level of ischaemic
damage caused by transplantation per se. Indeed, IRI rep-
resents an unavoidable event during solid organ transplan-
tation (SOT), and signiﬁcantly participates to early graft
dysfunction and enhanced graft immunogenicity [16, 41].
On the basis of the immunomodulatory, anti-inﬂammatory
and tissue repair properties of MSC, such a therapy has been
proposed in the ﬁeld of SOT. Indeed, MSC could in theory at-
tenuate the consequences of both IRI and AR following trans-
plantation, as well as prevent long-term allograft pathology. A
large number of animal transplant studies using MSC or MSC
derivatives have demonstrated that such therapy improves the
outcome of SOT via both paracrine and cell-dependent mech-
anisms of action [41, 42]. In the particular ﬁeld of KT, MSC
were shown to ameliorate inﬂammation caused by prolonged
cold ischaemia [43]. However, the best timing of MSC infusion
capable of promoting long-term immune tolerance without
impairing early graft function remains controversial [44, 45].
In a highly mismatched donor–recipient rat KT model, preo-
perative application of MSC resulted in enhanced humoral
immune responses, increased inﬂammation and rejection and
higher degree of kidney cortex tissue damage [44]. In contrast,
in a mouse model of fully allogeneic Balb/c kidney transplant
in C57 recipients presensitized by donor cell infusion, MSC in-
fusion prior to KT induced a signiﬁcant prolongation of
kidney graft survival by early expansion of Tregs in lymphoid
organs [45]. In this particular mouse model characterized by a
high frequency of donor-reactive memory T cells, MSC
therapy after KT caused premature graft dysfunction, with an
increased recruitment of neutrophils and complement C3
deposition into the graft. These observations raise questions
regarding the best timing for MSC administration at the time
of KT, with the dual hazard of MSC pre-sensitization and/or
MSC-associated engraftment syndrome. In a rat model of
CAN, MSC therapy prevented long-term interstitial ﬁbrosis
and tubular atrophy [46].
Following on these promising observations from pre-clini-
cal models, clinical trials were designed to assess the putative
beneﬁts of MSC therapy in human transplant recipients, with
a particular focus on graft outcomes and patient quality of life.
The Mesenchymal Stem Cells in Solid Organ Transplantation
(MiSOT) Consortium was founded to enable effective collab-
oration between research groups working in the application of
adherent stem cell products in SOT. The 2012 MiSOT report
includes six clinical trials applying MSC in SOT. MSC admin-
istration in clinical transplantation has proved relatively safe
and feasible. Preliminary data indicate that MSC may (i)
prevent AR, (ii) induce systemic alloimmune modulation and
(iii) reduce induction and maintenance immunosuppressive
regimens [47]. MSC administration also attenuates tubulitis
and interstitial ﬁbrosis/tubular atrophy in some patients,
thereby favouring long-term stable graft function. However,
several issues, including proper timing, concomitant immuno-
suppression, source and immunogenicity of MSC and their
potential oncogenicity, remain to be addressed before advising
a broader application of MSC therapy in SOT [47]. In particu-
lar, lessons can be learned from the tailor-made step-wise ap-
proach of Remuzzi et al. [48, 49]. In a pilot study of safety and
feasibility, two living-related donor kidney recipients were
given autologous MSC ‘at day 7 post-transplant’, after induc-
tion therapy with basiliximab/low-dose thymoglobulin [48].
In both patients, MSC therapy caused a pro-tolerogenic
environment characterized by lower CD8+ T cells, higher
CD4+ Treg and reduced donor-speciﬁc CD8+ T-cell cytotox-
icity. However, both MSC-treated patients developed AKI
early following MSC infusion, with graft recruitment of neu-
trophils and in situ complement-C3 deposition [48]. The
authors hypothesized that KT surgery triggered graft inﬂam-
mation causing an engraftment syndrome characterized by a
local recruitment and activation of MSC towards a pro-inﬂam-
matory phenotype. In a second clinical attempt, two living-
related kidney recipients were infused with autologous MSC
24 h before KT [49]. In addition, the anti-IL-2-receptor mono-
clonal antibody, basiliximab, was removed from the induction
regimen since it had been associated with a transient decrease
of circulating CD25+FoxP3+ regulatory Treg. In this clinical
setting, no engraftment syndrome was observed in the early
post-transplant phase. However, one patient developed AR 2
weeks post KT [49]. The expansion of CD25+FoxP3+ Treg was
similar in MSC-treated patients with or without basiliximab
induction. Altogether, these pilot MiSOT clinical trials will
help further amend MSC protocol in KT, thereby deﬁning the
most favourable conditions for long-term tolerance while cir-
cumventing early adverse effects.
PERSPECTIVES
AKI represents a worldwide public health issue of increasing
incidence, which is associated with a signiﬁcant morbi-
mortality. Treatment of patients presenting with AKI mostly
relies on supportive manoeuvres, in the absence of speciﬁc
target-orientated therapy. The pathophysiology of AKI com-
monly involves IRI, which leads to both immune and meta-
bolic consequences in renal tissue. Because MSC have
demonstrated immunomodulatory and tissue repair proper-
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times could attenuate IRI severity and accelerate the regener-
ation process. Their impact on kidney IC, i.e. before IRI,
remains to be assessed. Even more promising, MSC derivatives
have proved efﬁcient in animal models of AKI, which further
emphasizes the role of paracrine mediators in MSC therapy
and may help avoid total cell infusion. In SOT, MSC could
help cure both IRI and AR, thereby limiting graft immuno-
genicity and increasing its function and survival. MSC therapy
in animal models and in pilot clinical trials shows encouraging
results and opens novel avenues in the management of both
AKI and KT.
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